US Supreme Court to decide on gene patents in Myriad case
Cancer-testing company Myriad Genetics is back in the courts again. In a long-running piece of legislation, the Supreme Court today agreed to hear arguments about the validity of Myriad’s patents covering isolated DNA of the genes BRCA1 and BRCA2. Read more
Recent comments on this blog
Experiments reveal that crabs and lobsters feel pain
US research ethics agency upholds decision on informed consent
Chemistry credit disputes under the spotlight
Chemistry credit disputes under the spotlight
Contamination created controversial ‘acid-induced’ stem cells